Company intelligence / Profile preview

Eiken Chemical

Taito-ku, Tokyo, Japan

Ownership: Private
Employees: ~900
Development stage: Other

Overview

Eiken Chemical has achieved global adoption of diagnostic technologies such as the OC-Sensor FIT system for colorectal cancer, and its LAMP genetic testing platform has been applied in infectious disease diagnostics including tuberculosis and COVID-19; recent launches include lung cancer CDx kits (MINtS).

Therapeutic areas: NephrologyOncologyInfectious DiseasesMetabolic Disorders
Modalities: Diagnostic reagentDeviceMolecular test (LAMP)Immunological reagentSerological reagentBiochemical reagent
Industry: Molecular Diagnostics

Partnerships

Otsuka PharmaceuticalFINDTosoh Corporation

Beyond the preview

Go deeper on Eiken Chemical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Eiken Chemical.

Explore the full profile